keyword
MENU ▼
Read by QxMD icon Read
search

gallium 68 PSMA

keyword
https://www.readbyqxmd.com/read/29786490/gallium-68-psma-11-pet-mr-imaging-in-patients-with-intermediate-or-high-risk-prostate-cancer
#1
Sonya Youngju Park, Claudia Zacharias, Caitlyn Harrison, Richard E Fan, Christian Kunder, Negin Hatami, Frederik Giesel, Pejman Ghanouni, Bruce Daniel, Andreas M Loening, Geoffrey A Sonn, Andrei Iagaru
Purpose To report the results of dual-time-point gallium 68 (68 Ga) prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/magnetic resonance (MR) imaging prior to prostatectomy in patients with intermediate- or high-risk cancer. Materials and Methods Thirty-three men who underwent conventional imaging as clinically indicated and who were scheduled for radical prostatectomy with pelvic lymph node dissection were recruited for this study. A mean dose of 4.1 mCi ± 0.7 (151.7 MBq ± 25...
May 16, 2018: Radiology
https://www.readbyqxmd.com/read/29751842/psma-pet-based-radiotherapy-a-review-of-initial-experiences-survey-on-current-practice-and-future-perspectives
#2
REVIEW
Sebastian Zschaeck, Fabian Lohaus, Marcus Beck, Gregor Habl, Stephanie Kroeze, Constantinos Zamboglou, Stefan Alexander Koerber, Jürgen Debus, Tobias Hölscher, Peter Wust, Ute Ganswindt, Alexander D J Baur, Klaus Zöphel, Nikola Cihoric, Matthias Guckenberger, Stephanie E Combs, Anca Ligia Grosu, Pirus Ghadjar, Claus Belka
68 Gallium prostate specific membrane antigen (PSMA) ligand positron emission tomography (PET) is an increasingly used imaging modality in prostate cancer, especially in cases of tumor recurrence after curative intended therapy. Owed to the novelty of the PSMA-targeting tracers, clinical evidence on the value of PSMA-PET is moderate but rapidly increasing. State of the art imaging is pivotal for radiotherapy treatment planning as it may affect dose prescription, target delineation and use of concomitant therapy...
May 11, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/29726071/a-prospective-randomised-multi-centre-study-of-the-impact-of-ga-68-psma-pet-ct-imaging-for-staging-high-risk-prostate-cancer-prior-to-curative-intent-surgery-or-radiotherapy-propsma-study-clinical-trial-protocol
#3
Michael S Hofman, Declan G Murphy, Scott G Williams, Tatenda Nzenza, Alan Herschtal, Richard De Abreu Lourenco, Dale L Bailey, Ray Budd, Rodney J Hicks, Roslyn J Francis, Nathan Lawrentschuk
INTRODUCTION: Accurate staging of patients with prostate cancer is important for therapeutic decision making. Relapse following surgery or radiotherapy of curative intent is not uncommon and, in part, represents a failure of staging with current diagnostic imaging techniques to detect disease spread. Prostate-specific-membrane-antigen (PSMA) positron emission tomography / computed tomography (PET/CT) is a new whole body scanning technique that enables visualisation of prostate cancer with high contrast...
May 3, 2018: BJU International
https://www.readbyqxmd.com/read/29719490/can-gallium-68-prostate-specific-membrane-antigen-ligand-be-a-potential-radiotracer-for-renal-cortical-positron-emission-tomography-imaging
#4
Ismet Sarikaya, Abdelhamid H Elgazzar, Mahmoud A Alfeeli, Ali Sarikaya
Gallium-68 prostate-specific membrane antigen (Ga-68 PSMA) ligand (HBED-CC) is a new promising positron emission tomography (PET) tracer for prostate cancer. Intense renal parenchymal uptake is a physiologic finding on Ga-68 PSMA ligand PET images. Evaluation of kidneys in low intensity demonstrates excellent distribution of this radiotracer in renal parenchyma with excellent image quality and resolution. In this article, we present the Ga-68 PSMA ligand PET renal images of four patients with prostate cancer...
April 2018: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29719484/a-case-of-well-differentiated-hepatocellular-carcinoma-identified-on-gallium-68-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography
#5
Hian Liang Huang, Tracy Jie Zhen Loh, Pierce Kah Hoe Chow
Prostate-specific membrane antigen (PSMA) is a glycosylated type-II transmembrane protein highly expressed in certain tumor cells. To the best of our knowledge, this is the first case reported of an isolated well-differentiated hepatocellular carcinoma (HCC) strongly suspected on gallium-68 (68 Ga)-PSMA positron emission tomography/computed tomography (PET/CT), which was not well characterized both on magnetic resonance imaging (MRI) liver with Primovist as well as fluorine-18 (18 F)-choline PET/CT. Our patient had previous prostate cancer and previously was imaged using 18 F-choline PET/CT...
April 2018: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29719325/incremental-value-of-68-gallium-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-in-patients-with-abnormal-prostate-specific-antigen-and-benign-transrectal-ultrasound-biopsy
#6
Manoj Gupta, Partha Sarathi Choudhury, Sudhir Rawal, Gurudutt Gupta
Introduction: Bladder outlet obstruction due to prostate enlargement is a common health problem in male and frequently investigated with prostate-specific antigen (PSA) and transrectal ultrasound (TRUS). TRUS-guided biopsy is critical to differentiate benign prostatic hyperplasia (BPH) or prostate cancer (PCa) even though it has been associated with false negative with reported 3%-16% incidence of PCa in BPH specimens. Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), a targeted molecular imaging for PCa, has showed promising results in recurrence and staging...
April 2018: Urology Annals
https://www.readbyqxmd.com/read/29678358/impact-of-68-ga-psma-pet-on-the-management-of-patients-with-prostate-cancer-a-systematic-review-and-meta-analysis
#7
REVIEW
Sangwon Han, Sungmin Woo, Yeon Joo Kim, Chong Hyun Suh
CONTEXT: 68 Gallium prostate-specific membrane antigen positron emission tomography (68 Ga-PSMA PET) is an emerging imaging modality for assessment of prostate cancer. Recent studies show promising results regarding its ability to detect recurrent or metastatic prostate cancer superior to that of conventional imaging modalities. However, the impact of 68 Ga-PSMA PET on management of patients with prostate cancer has not been well established. OBJECTIVE: To perform a systematic review and meta-analysis to evaluate the impact of 68 Ga-PSMA PET on management of patients with prostate cancer...
April 17, 2018: European Urology
https://www.readbyqxmd.com/read/29664103/microfluidic-68-ga-labeling-a-proof-of-principle-study
#8
Sarah Pfaff, Cecile Philippe, Verena Pichler, Marcus Hacker, Markus Mitterhauser, Wolfgang Wadsak
Positron emission tomography (PET) as a tool for molecular imaging of cancer has gained huge interest in the last few years. Gallium-68 is a popular PET nuclide due to its favorable characteristics, like advantageous half-life (68 min) and independency of a cyclotron on-site for its production. Accordingly, several 68Ga-complexes for cancer imaging via PET have been made available during the last few years. In this work, 68Ga-labeled compounds were synthesized applying a commercially available microfluidic device for the first time...
April 17, 2018: Dalton Transactions: An International Journal of Inorganic Chemistry
https://www.readbyqxmd.com/read/29619657/hallmarks-in-prostate-cancer-imaging-with-ga68-psma-11-pet-ct-with-reference-to-detection-limits-and-quantitative-properties
#9
Alejandro Sanchez-Crespo, Emma Jussing, Ann-Charlotte Björklund, Katja Pokrovskaja Tamm
BACKGROUND: Gallium-68-labeled prostate-specific antigen positron emission tomography/computed tomography imaging (Ga68-PSMA-11-PET/CT) has emerged as a potential gold standard for prostate cancer (PCa) diagnosis. However, the imaging limitations of this technique at the early state of PCa recurrence/metastatic spread are still not well characterized. The aim of this study was to determine the quantitative properties and the fundamental imaging limits of Ga68-PSMA-11-PET/CT in localizing small PCa cell deposits...
April 4, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29572670/the-impact-of-68-ga-psma-i-t-pet-ct-on-radiotherapy-planning-in-patients-with-prostate-cancer
#10
Thorsten Frenzel, Milena Tienken, Merve Abel, Christoph Berliner, Susanne Klutmann, Dirk Beyersdorff, Rudolf Schwarz, Andreas Krüll, Peter Bannas
PURPOSE: To determine the impact of Gallium-68-labled prostate-specific membrane antigen positron-emission tomography/computed tomography ([68 Ga]PSMA PET/CT) on radiotherapy planning for primary disease, biochemical cancer relapse, and advanced disease of prostate cancer. METHODS: A total of 106 patients with prostate cancer scheduled for radiation therapy underwent 120 [68 Ga]PSMA PET/CT scans prior to radiotherapy treatment. In 20 cases, patients underwent [68 Ga]PSMA PET/CT for primary therapy (PT), 75 cases were referred for biochemical relapse after surgery (RL), and 25 cases were intended for palliative treatment of localized metastases (MD)...
March 23, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29571066/in-vitro-and-in-vivo-evaluation-of-the-bifunctional-chelator-nodia-me-in-combination-with-a-prostate-specific-membrane-antigen-targeting-vector
#11
Tilman Läppchen, Yvonne Kiefer, Jason P Holland, Mark D Bartholomä
INTRODUCTION: We recently developed a chelating platform based on the macrocycle 1,4,7-triazacyclononane with up to three five-membered azaheterocyclic arms for complexation of the PET nuclides gallium-68 and copper-64. The main objective of this study was to evaluate the stability and pharmacokinetics of68 Ga- and64 Cu-complexes of the bifunctional chelator NODIA-Me 1 covalently bound to a PSMA targeting vector in vivo. METHODS: NODIA-Me 1 was conjugated to the PSMA targeting Glu-NH-CO-NH-Lys moiety to give the bioconjugate NODIA-Me-NaI-Ahx-PSMA 4...
March 10, 2018: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29565650/recent-advances-in-theranostics-and-challenges-for-the-future
#12
J Harvey Turner
Theranostic nuclear oncology is on the cusp of adoption into routine clinical management of neuroendocrine tumours (NETs) following publication of the Phase 3 randomised controlled trial, NETTER-1. For the first time, level 1b evidence of efficacy and safety of 68-gallium/177-lutetium-DOTA-octreotate peptide receptor radionuclide therapy, of mid-gut neuroendocrine tumours was established. Multicentre Phase 2 studies of 68-gallium/177-lutetium-prostate specific membrane antigen theranostic approaches to management of end-stage metastatic castrate-resistant prostate cancer, are also very encouraging...
March 29, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29528713/effect-of-combined-68-ga-psmahbed-cc-uptake-pattern-and-multiparametric-mri-derived-with-simultaneous-pet-mri-in-the-diagnosis-of-primary-prostate-cancer-initial-experience
#13
Sangeeta Taneja, Amarnath Jena, Rajesh Taneja, Aru Singh, Aashim Ahuja
OBJECTIVE: The purpose of this study is to assess whether temporal changes in 68 Ga-prostate-specific membrane antigen (PSMA)-HBED-CC uptake and multiparametric MRI parameters derived using PET/MRI can aid in characterization of benign and malignant prostate lesions. MATERIALS AND METHODS: Thirty-five men with 29 malignant and six benign prostate lesions undergoing complete clinical workup including histologic analysis were enrolled for this retrospective study...
March 12, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29439481/review-of-gallium-68-psma-pet-ct-imaging-in-the-management-of-prostate-cancer
#14
REVIEW
Nat P Lenzo, Danielle Meyrick, J Harvey Turner
Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by 68 Ga-PSMA-positron emission tomography/computed tomography (68 Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to have superseded CT, and appears superior to MR imaging, for the detection of metastatic disease. 68 Ga-PSMA PET/CT has the ability to reliably stage prostate cancer at presentation and can help inform an optimal treatment approach...
February 11, 2018: Diagnostics
https://www.readbyqxmd.com/read/29430118/penile-metastasis-from-prostate-cancer-presenting-as-malignant-priapism-detected-using-gallium-68-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography
#15
Koramadai Karuppusamy Kamaleshwaran, Barani Kumar Pollachi Balasundararaj, Raghi Jose, Ajit Sugunan Shinto
Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (Ga-68 PSMA PET/CT) is a promising diagnostic tool for patients with prostate cancer. Penile metastasis from prostate cancer is a rare phenomenon that infrequently manifests as malignant priapism. We present a case of 79-year-old patient diagnosed as a case of adenocarcinoma prostate presenting with penile metastases imaged using Ga-68 PSMA PET/CT.
January 2018: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/29320333/prostate-specific-membrane-antigen-pet-clinical-utility-in-prostate-cancer-normal-patterns-pearls-and-pitfalls
#16
Michael S Hofman, Rodney J Hicks, Tobias Maurer, Matthias Eiber
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in prostate cancer. Radiolabeled small molecules that bind with high affinity to its active extracellular center have emerged as a potential new diagnostic standard of reference for prostate cancer, resulting in images with extraordinary tumor-to-background contrast. Currently, gallium 68 (68 Ga)-PSMA-11 (or HBED-PSMA) is the most widely used radiotracer for PSMA positron emission tomography (PET)/computed tomography (CT) or PSMA PET/magnetic resonance (MR) imaging...
January 2018: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29291425/lymphangitic-carcinomatosis-from-prostate-cancer-identified-with-gallium-68-prostate-specific-membrane-antigen-positron-emission-tomography-imaging
#17
Victor D Tang, Patrina Campbell, David A Pattison
Lymphangitic carcinomatosis refers to the rare process of diffuse malignant invasion of the pulmonary lymphatics. We describe the first reported case of lymphangitic carcinomatosis visualized with gallium-68 prostate-specific membrane antigen positron emission tomography and its clinical significance in a 53-year-old man with prostate carcinoma. This case highlights the ability of gallium-68 prostate-specific membrane antigen positron emission tomography for prostate carcinoma characterization and the importance of always considering atypical patterns of metastatic disease...
April 2018: Urology
https://www.readbyqxmd.com/read/29242404/comparison-of-68-ga-psma-11-and-18-f-fluciclovine-pet-ct-in-a-case-series-of-10-patients-with-prostate-cancer-recurrence
#18
Jeremie Calais, Wolfgang P Fendler, Ken Herrmann, Matthias Eiber, Francesco Ceci
This was a head-to-head comparison between 68 Ga-labeled prostate-specific membrane antigen (PSMA)-11 and 18 F-fluciclovine PET/CT in a series of 10 patients with prostate cancer (PCa) recurrence. Methods: In total, 288 patients with PCa recurrence were enrolled in a prospective study of 68 Ga-PSMA-11 PET/CT imaging for recurrent disease localization (ClinicalTrials.gov identifier NCT02940262). We retrospectively identified 10 patients who underwent clinically indicated 18 F-fluciclovine PET/CT prior to enrollment...
May 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29242398/impact-of-68-ga-psma-11-pet-ct-on-the-management-of-prostate-cancer-patients-with-biochemical-recurrence
#19
Jeremie Calais, Wolfgang P Fendler, Matthias Eiber, Jeannine Gartmann, Fang-I Chu, Nicholas G Nickols, Robert E Reiter, Matthew B Rettig, Leonard S Marks, Thomas E Ahlering, Linda M Huynh, Roger Slavik, Pawan Gupta, Andrew Quon, Martin S Allen-Auerbach, Johannes Czernin, Ken Herrmann
In this prospective survey of referring physicians, we investigated whether and how68 Ga-labeled prostate-specific membrane antigen 11 (68 Ga-PSMA-11) PET/CT affects the implemented management of prostate cancer patients with biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05-202 ng/mL). Referring physicians completed one questionnaire before the scan to indicate the treatment plan without68 Ga-PSMA-11 PET/CT information (Q1; n = 101), one immediately after the scan to denote intended management changes (Q2; n = 101), and one 3-6 mo later to document the final implemented management (Q3; n = 56)...
March 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29158832/clinical-translation-and-first-in-human-use-of-44-sc-sc-psma-617-for-pet-imaging-of-metastasized-castrate-resistant-prostate-cancer
#20
Elisabeth Eppard, Ana de la Fuente, Martina Benešová, Ambreen Khawar, Ralph A Bundschuh, Florian C Gärtner, Barbara Kreppel, Klaus Kopka, Markus Essler, Frank Rösch
BACKGROUND: Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life of gallium-68 this positron emitter precludes prolonged acquisition periods, as required for pre-therapeutic dosimetry or intraoperative applications...
2017: Theranostics
keyword
keyword
104755
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"